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Endothelial cell-specific molecule 1 (endocan) and IMA play a role in endothelial dysfunction as mediators of systemic inflammation and oxidative stress, and they are associated with cardiovascular (CV) disease and CV mortality. [2] [3] [4] It has also been shown that serum endocan and IMA levels were significantly higher in infectious and other chronic diseases. [5] [6] [7] Balamir et al 1 did not mention whether acute or chronic infectious disease was an exclusion criterion in their study. Besides, how did the authors ensure the exclusion of infection in the presence of elevated serum high-sensitivity C-reactive protein (hsCRP) level (Table 4 ; maximum hsCRP level was 187.53 mg/L in the diabetic patients with endothelial dysfunction). 1 Another important issue is that many easily available and reliable inflammatory and oxidative biomarkers such as white blood cell, neutrophil, lymphocyte, monocyte, red cell distribution width, erythrocyte sedimentation rate, and serum total bilirubin have been demonstrated to be independent risk factors and prognostic markers of endothelial dysfunction. [8] [9] [10] Therefore, the authors should have provided details about at least some of these biochemical laboratory parameters as well as clinical data or imaging tools that may be needed when reaching a definitive diagnosis. It is important for clinicians to decide whether increased serum endocan and IMA levels are due to T2DM or other reasons, including infection.
As a final query, was there a positive correlation of hsCRP level with endocan and IMA levels?
In conclusion, serum endocan and IMA may be independent risk factors for endothelial dysfunction among patients with T2DM. However, confounding factors should be considered when interpreting these levels. 
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